Figure 1. Duration of Treatment and Response in Patients With Metastatic Urothelial Cancer Treated With Atezolizumab.

Time in study is plotted for patients with confirmed, investigator-assessed Response Evaluation Criteria in Solid Tumors version 1.1 responses. Bar color indicates treatment or retreatment status, and symbols, response assessments. Thin bars indicate off-treatment periods. Ongoing response indicates no observation of progressive disease (PD) or death. CR indicates complete response; and PR, partial response.

^a Subsequent, postretreatment response calculated after rebaselining of target lesion diameters at time of retreatment. No PD or death following subsequent response.

^b Patient is deceased.